A cost-minimization analysis of telemedicine vs standard induction for buprenorphine: Evidence from a randomized clinical trial in India.

Background: In-person buprenorphine induction poses substantial cost and access barriers in India's opioid agonist treatment programs, while telemedicine-assisted induction may offer a scalable, lower-cost alternative. Aim: To compare the societal costs of telemedicine-assisted buprenorphine inducti...

Descripción completa

Detalles Bibliográficos
Publicado en:Indian Journal of Psychiatry Vol. 68; no. 7; pp. 609 - 616
Autores principales: Singh, Amudeep, Dhillon, Harpreet S., Purohit, Neha, Ghosh, Abhishek, Naik, Shalini, Subodh, BN, Basu, Debasish, Shankar, Prinja
Formato: research tables/charts Journal Article
Publicado: Wolters Kluwer India Pvt Ltd Jul2026
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=195473335&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 195473335
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00195545
        GDJ
      jtl: Indian Journal of Psychiatry
      issn: 00195545
      maglogo: N
    pubinfo:
      dt: Jul2026
      vid: 68
      iid: 7
      pid: 16919
      pub: Wolters Kluwer India Pvt Ltd
    artinfo:
      ui:
        195473335
        195473335
        195473335
        10.4103/indianjpsychiatry_116_26
        195473335
      ppf: 609
      ppct: 7
      formats:
      tig:
        atl: A cost-minimization analysis of telemedicine vs standard induction for buprenorphine: Evidence from a randomized clinical trial in India.
      aug:
        au:
          Singh, Amudeep
          Dhillon, Harpreet S.
          Purohit, Neha
          Ghosh, Abhishek
          Naik, Shalini
          Subodh, BN
          Basu, Debasish
          Shankar, Prinja
        affil: Department of Community Medicine and School of Public Health, Post Graduate Institute of Medical Education and Research, Chandigarh, India
      sug:
        subj:
          Telemedicine
          Buprenorphine Therapeutic Use
          Health Care Costs Evaluation
          Cost Savings
          Quality of Life
          Research Subject Retention
          Outcomes (Health Care)
          India
          Human
          Health Expenditures
          Descriptive Statistics
          Comparative Studies
          Outpatients
          Tertiary Health Care
          Questionnaires
          Stratified Random Sample
          Summated Rating Scaling
          Interviews
          Data Analysis Software
          Unpaired T-Tests
          Patient-Reported Outcomes
          Psychiatric Patients Psychosocial Factors
          Persons with Substance Use Disorders Psychosocial Factors
          Substance Use Disorders Drug Therapy
          Narcotics
      ab: Background: In-person buprenorphine induction poses substantial cost and access barriers in India's opioid agonist treatment programs, while telemedicine-assisted induction may offer a scalable, lower-cost alternative. Aim: To compare the societal costs of telemedicine-assisted buprenorphine induction (TABI) with standard care (SOC), while evaluating treatment retention and quality-of-life (QoL) outcomes. Methods: An economic evaluation was embedded within a randomized controlled trial at a tertiary addiction treatment center, adopting a societal perspective. Health-system costs were estimated using a mixed top-down/bottom-up micro-costing approach for all participants (n = 138; SOC = 70, TABI = 68), while direct out-of-pocket and indirect wage-loss costs were assessed on day 7 in a predefined sub-sample (n = 57; SOC = 28, TABI = 29). Primary outcomes were 1-week retention and QoL; as effectiveness was comparable between arms, a cost-minimization analysis (CMA) was conducted. Results: Mean health-system cost per induction was INR 3,545 (USD 42.26) for SOC vs INR 2,690 (USD 32.06) for TABI (24% lower). In the out-of-pocket expenditure (OOP) sub-sample, mean direct patient costs were INR 1,857 (USD 22.13) for SOC vs INR 776 (USD 9.24) for TABI (P < 0.001); mean indirect costs were INR 1,502 (USD 17.91) vs INR 766 (USD 9.13). Total mean societal cost per patient was INR 6,904 (USD 82.33) for SOC vs INR 4,232 (USD 31.88) for TABI (39% saving). Treatment retention was similar between groups (SOC: 76% vs TABI: 82%; P = 0.339), and both demonstrated comparable improvements in QoL at 1 week (84.00 vs 84.17; P = 0.912). Conclusion: Compared with standard induction, TABI substantially reduces health-system and patient costs, while maintaining comparable short-term retention and QoL.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N